Vectus Biosystems Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VBS.AX research report →
Price Chart
About the company
Vectus Biosystems Limited, an Australian medical research and development firm, specializes in devising therapies for fibrotic conditions and hypertension. Its pharmaceutical pipeline addresses ailments affecting the heart, kidneys, liver, and lungs. The company's leading experimental drug, VB0004, aims to counter the degradation of functional tissue resulting from fibrosis, scarring, and elevated blood pressure.
- CEO
- Tara Speranza
- IPO
- 2016
- Employees
- 5
- HQ
- Rosebery, NSW, AU
Get TickerSpark's AI analysis on VBS.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $9.90M
- P/E
- -6.06
- PEG
- -0.13
- P/S
- 117.18
- P/B
- -10.58
- EV/EBITDA
- -7.23
- Div Yield
- 0.00%
- Gross Margin
- 98.13%
- Op Margin
- -1646.01%
- Net Margin
- -1667.94%
- ROE
- 265.12%
- ROIC
- 391.25%
Latest fiscal year · YoY change
- Revenue
- $478.18K-58.0%
- Gross Profit
- $478.18K-58.0%
- Op Income
- $-1,687,743
- Net Income
- $-1,777,259+24.0%
- EPS
- $-0.03+23.9%
- OCF Growth
- +59.2%
- FCF Growth
- +60.5%
- 52W High
- $0.46
- 52W Low
- $0.05
- 50D MA
- $0.15
- 200D MA
- $0.15
- Beta
- 0.29
- RSI (14)
- 53
- Avg Volume
- 36.46K
No earnings-call transcripts are available for VBS.AX yet.
- Free Float
- 39.9%
- Shares Outstanding
- 61.87M
- Float Shares
- 24.65M
Our VBS.AX coverage
Recent articles, reports, and earnings notes.
No research on VBS.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VBS.AX report →